Drug Trial Radar · NCT07944482
A Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal Liver Function
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jul 3, 2026
Primary completion
Dec 31, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Fujian Akeylink Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, non-randomized, open-label, parallel-group, single-dose study designed to evaluate the pharmacokinetic profiles and safety of GST-HG141 tablets in participants with hepatic impairment.
Conditions
- Chronic Hepatitis b
Interventions
GST-HG141Drug
GST-HG141 will be administered as a single oral dose on the morning of day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax) for GST-HG141Time frame: up to 6 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.